Product
FB825
Aliases
FB825 in intravenous route, FB825 or Placebo in subcutaneous route
3 clinical trials
2 indications
Indication
Atopic DermatitisIndication
AsthmaClinical trial
A Randomized, Placebo-Controlled, Double-Blind, Phase I Study to Evaluate the Safety and Bridging Pharmacokinetics Profile of FB825 for Single Subcutaneous Administration in Healthy AdultsStatus: Active (not recruiting), Estimated PCD: 2024-03-26
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic DermatitisStatus: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase II Study to Evaluate the Efficacy and Safety of FB825 in Adult Patients With Moderate-to-severe Allergic AsthmaStatus: Recruiting, Estimated PCD: 2024-06-01